The Technical Analyst
180 Life Sciences Corp. [ATNF]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
180 Life Sciences Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.56% $1.900
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.620 mill |
| EPS: | -52.59 |
| P/E: | -0.0400 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 0.853 mill |
| Avg Daily Volume: | 0.107 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0400 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0400 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.730 (-8.96%) $-0.170 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.400 - 2.40 ( +/- 26.32%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-28 | Jordan Blair | Buy | 0 | |
| 2024-03-07 | Jimenez Omar | Buy | 0 | |
| 2024-03-07 | Smith Ryan Lewis | Buy | 0 | |
| 2023-12-28 | Feldmann Marc | Buy | 135 377 | Common Stock |
| 2023-12-15 | Feldmann Marc | Sell | 25 000 | Common Stock |
| INSIDER POWER |
|---|
| 91.97 |
| Last 97 transactions |
| Buy: 4 377 554 | Sell: 589 695 |
Forecast:
16:00 - $1.950
Live Trading Signals (every 1 min)
Forecast
1: 15:54 - $1.905
Forecast 2: 16:00 - $1.950
Forecast 3: 16:00 - $1.950
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.900 (5.56% ) |
| Volume | 0.0480 mill |
| Avg. Vol. | 0.107 mill |
| % of Avg. Vol | 45.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATNF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ATNF
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-14 08:30:00 - Press Release
180 Life Sciences Regains Full Compliance With Nasdaq Minimum Bid Price Requirement
Palo alto, calif., march 14, 2024 (globe newswire) -- 180 life sciences corp. (nasdaq: atnf) (“180 life sciences” or the “company”), today announced that the company received a letter on march 13, 2024 from the nasdaq stock market llc (“nasdaq”) indicating that the company has regained full compliance with the minimum bid price for continued listing on the nasdaq pursuant to nasdaq listing rule 5550(a)(2) (“minimum bid price requirement”).
2024-02-26 07:00:00 - Press Release
180 Life Sciences Corp. Announces 1-for 19 Reverse Stock Split As Part Of Nasdaq Compliance Plan
Palo alto, calif., feb. 26, 2024 (globe newswire) -- 180 life sciences corp. (nasdaq: atnf) (“180 life sciences” or the “company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “reverse stock split”). the reverse stock split is expected to become effective on february 28, 2024 at 12:01 p.m. eastern time (the “effective time”), with shares expected to begin trading on the nasdaq capital market, on a split-adjusted, at market open on february 28, 2024. in connection with the reverse stock split, every 19 shares of the company's common stock issued and outstanding as of the effective time will be automatically converted into one share of the company's common stock...
2023-12-04 09:00:00 - Press Release
180 life sciences Engages Financial Advisor To Explore Strategic Alternatives
Palo alto, calif., dec. 04, 2023 (globe newswire) -- 180 life sciences corp. (nasdaq: atnf) (“180 life sciences” or the “company”), today announced it has engaged a.g.p./alliance global partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.
2023-11-28 09:00:00 - Press Release
180 life sciences Announces Review Of Strategic Alternatives
Palo alto, calif., nov. 28, 2023 (globe newswire) -- 180 life sciences corp. (nasdaq: atnf) (“180 life sciences” or the “company”), today announced that its board of directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. in consultation with financial and legal advisors, the company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.
2023-08-14 16:29:00 - Press Release
180 Life Sciences Corp. Announces Closing Of $3 Million Public Offering
Palo alto, calif., aug. 14, 2023 (globe newswire) -- 180 life sciences corp. (nasdaq: atnf, “180 life sciences” or the “company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. the warrants are immediately exercisable at an exercise price of $0.65 per share and will expire october 10, 2028. the gross proceeds from the offering are approximately $3 million, before deducting the placement agent's fees and other offering expenses.
Latest News
2023-08-09 08:06:35 - InvestorPlace
Why Is 180 Life Sciences (ATNF) Stock Up 38% Today?
180 Life Sciences (NASDAQ: ATNF ) stock is climbing higher on Wednesday as the cannabis market undergoes a rally. The cannabis sector has been on the rise lately as several companies in it release earnings reports.
2023-05-21 06:00:00 - PennyStocks
Penny Stock Investing, 3 High-Growth Industries to Watch
Take a look at these 3 industries to find penny stocks in The post Penny Stock Investing, 3 High-Growth Industries to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-05-19 12:57:00 - PennyStocks
5 Top Penny Stocks To Watch Today; Time To Buy?
5 hot penny stocks to watch right now. The post 5 Top Penny Stocks To Watch Today; Time To Buy?
2023-01-09 06:00:00 - PennyStocks
Using News to Find Penny Stocks to Buy: 3 Tips
Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-06 12:27:27 - PennyStocks
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
2022-12-31 11:00:00 - PennyStocks
3 Essential Strategies for Penny Stocks Trading in 2023
Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-12-24 16:27:01 - InvestorPlace
The 7 Most Sold-Off Stocks of 2022
With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to garner lessons from the worst-hit market ideas.
2022-12-19 08:43:40 - Pulse2
180 Life Sciences (ATNF) Stock: 1-For-20 Reverse Split Goes Into Effect
A 1-for-20 reverse split of 180 Life Sciences (ATNF) stock has gone into effect. These are the details.
2022-06-15 08:28:03 - Benzinga
Why 180 Life Sciences Shares Are Plunging Today
180 Life Sciences Corp (NASDAQ: ATNF) received a written response from the U.K.'s regulatory agency and U.S. FDA related to questions submitted in a Type C meeting request for anti-TNF treatment, adalimumab, to treat early-stage Dupuytren's disease. Dupuytren's disease.
2022-01-31 08:31:46 - Pulse2
180 Life Sciences (ATNF) Stock: Why The Price Jumped Up Today
The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 11% pre-market today. This is why it happened.